Document:

Amendment No. 2 to Amended and Restated Credit Agreement

 Exhibit 4.1 
 EXECUTION COPY 
 AMENDMENT NO. 2 TO AMENDED AND RESTATED CREDIT AGREEMENT 
 This Amendment No. 2 (this “Amendment”) is entered into as of September 27, 2007 by and among BIO-RAD LABORATORIES, INC., a
Delaware corporation (the “Borrower”), certain of the financial institutions party to the below-defined Credit Agreement (collectively, the “Lenders”) and JPMORGAN CHASE BANK, N.A. (successor by merger to Bank One,
NA (Main Office Chicago)), as one of the Lenders and in its capacity as contractual representative (the “Agent”) on behalf of itself and the other Lenders. 
 RECITALS: 
 WHEREAS, the Borrower, the Lenders and the Agent have entered into that
certain Amended and Restated Credit Agreement dated as of June 21, 2005 (the “Credit Agreement”); 
 WHEREAS, the
Borrower wishes to amend the Credit Agreement in certain respects and the Lenders and the Agent are willing to amend the Credit Agreement on the terms and conditions set forth herein; 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as
follows: 
 1. Defined Terms. Capitalized terms used herein and not otherwise defined herein shall have the meanings attributed to such
terms in the Credit Agreement. 
 2. Amendments to Credit Agreement. Upon the effectiveness of this Amendment in accordance with the
provisions of Section 3 below, the Credit Agreement is hereby amended as follows: 
 (a) Section 1.01
of the Credit Agreement is hereby amended to restate the definition of “Commitment” in its entirety follows: 
 “Commitment” means, for each Lender, the obligation of such Lender pursuant to Section 2.1 to make Revolving Loans and pursuant to Section 2.4.2 to purchase participations in Letters of Credit and pursuant to
Section 2.5 to participate in Swing Line Loans not exceeding the amount set forth opposite its name on the Commitment Schedule or as set forth in any assignment agreement relating to any assignment that has become effective pursuant to
Section 12.3.2, as such amount may be modified from time to time pursuant to the terms hereof. 
 (b)
Section 1.01 of the Credit Agreement is hereby amended to insert the following new defined term therein in the appropriate alphabetical order: 
 “Commitment Schedule” means the Schedule attached hereto identified as such. 

 “DiaMed” means DiaMed Holding AG a stock corporation
(Aktiengesellschaft) organized under Swiss law, registered in the commercial register of the canton of Freiburg under registration number CH-217-0530150-3 and having its corporate seat in Cressier, Switzerland. 
 “DiaMed Acquisition” means the acquisition by the Borrower, directly or indirectly, of all issued and outstanding
shares of DiaMed. 
 (c) Section 2.6(B) of the Credit Agreement is hereby amended to delete the reference to
“$200,000,000” set forth therein and to substitute “$250,000,000” therefor. 
 (d)
Section 6.11 of the Credit Agreement is hereby amended to (1) redesignate clause (xiii) thereof as clause (xv) and to delete the reference to “(xii)” set forth therein and to substitute “(xiv)”
therefor, and (2) insert new clauses (xiii) and (xiv) therein as follows: 
 (xiii) Intercompany
Indebtedness of Bio-Rad Luxembourg S.à.r.l. to the Borrower with respect to the loan made to Bio-Rad Luxembourg S.à.r.l. by the Borrower in connection with the DiaMed Acquisition in an aggregate amount (together with the aggregate
amount of outstanding Investments permitted under Section 6.14(ix)) not to exceed $500,000,000. 
 (xiv)
Indebtedness of DiaMed in an aggregate amount not to exceed $60,000,000. 
 (e) Section 6.14(v) of the Credit
Agreement is hereby amended to restate clause (A) thereof in its entirety as follows: 
 (A) (i) Permitted
Acquisitions and (ii) the DiaMed Acquisition and 
 (f) Section 6.14 of the Credit Agreement is hereby
amended to (1) redesignate clause (ix) thereof as clause (xi) and to delete the reference to “(i) through (viii)” set forth therein and to substitute “(i) through (x)” therefor and to delete the reference to
“this clause (ix)” set forth therein and to substitute “this clause (xi)” therefor, and (ii) insert new clauses (ix) and (x) therein as follows: 
 (ix) Investments by the Borrower in Bio-Rad Luxembourg S.à.r.l. in connection with the DiaMed Acquisition in an aggregate amount
(together with the aggregate amount of outstanding Intercompany Indebtedness permitted under Section 6.11(xiii)) not to exceed $500,000,000. 
 (x) Investments held by DiaMed in an aggregate amount not to exceed $25,000,000; provided that Investments made in reliance on this clause (x) may only remain outstanding under this clause (x) for
the period beginning on the date that the Borrower acquires, directly or indirectly, greater than 50% of the issued and outstanding shares of DiaMed in connection with the DiaMed Acquisition and ending on the date ninety (90) days thereafter.

  

 2 

 (g) Section 6.15 of the Credit Agreement is hereby amended to
(1) redesignate clause (xiii) thereof as clause (xv) and to delete the reference to “(xii)” set forth therein and to substitute “(xiv)” therefor, and (2) insert new clauses (xiii) and (xiv) therein
as follows: 
 (xiii) Liens to secure Indebtedness permitted under Section 6.11(xiv). 
 (xiv) Liens assumed in connection with the DiaMed Acquisition, the aggregate amount of liabilities secured by which does not exceed
$10,000,000; provided that Liens existing in reliance on this clause (xiv) may only remain in existence under this clause (xiv) for the period beginning on the date that the Borrower acquires, directly or indirectly, greater than
50% of the issued and outstanding shares of DiaMed in connection with the DiaMed Acquisition and ending on the date ninety (90) days thereafter. 
 (h) A new Commitment Schedule is hereby added to the Credit Agreement as set forth on Exhibit A hereto. 
 3. Conditions of Effectiveness. This Amendment shall become effective and be deemed effective as of the date hereof (the “Effective Date”) if, and only if, the Agent shall have received (i) duly executed
originals of this Amendment from the Borrower and the Lenders and (ii) such other documents, instruments and legal opinions as are reasonably requested by the Agent in connection with this Amendment. Delivery of an executed counterpart of a
signature page of this Amendment by e-mail or facsimile shall be effective as delivery of a manually executed counterpart of this Amendment. 
 4. Representations and Warranties of the Borrower. The Borrower represents and warrants to the Lenders that, as of the Effective Date and giving effect to this Amendment: 
 (a) there exists no Default or Unmatured Default; and 
 (b) the representations and warranties contained in Article V of the Credit Agreement are true and correct in all material respects
as of the Effective Date except to the extent any such representation or warranty is stated to relate solely to an earlier date, in which case such representation or warranty was true and correct on and as of such earlier date. 
 5. Reference to and Effect on the Credit Agreement. 
 (a) Upon the effectiveness of this Amendment pursuant to Section 3 hereof, on and after the Effective Date each reference in the Credit Agreement to “this Agreement,” “hereunder,”
“hereof,” “herein” or words of like import and each reference to the Credit Agreement in each other Loan Document shall mean and be a reference to the Credit Agreement as modified hereby. 
 (b) Except as specifically waived or amended herein, all of the terms, conditions and covenants of the Credit Agreement and the other Loan
Documents shall remain in full force and effect and are hereby ratified and confirmed. 
  

 3 

 (c) The execution, delivery and effectiveness of this Amendment shall not, except as
expressly provided herein, operate as a waiver of (i) any right, power or remedy of any Lender or the Agent under the Credit Agreement or any of the Loan Documents, or (ii) any Default or Unmatured Default under the Credit Agreement.

 6. CHOICE OF LAW. THIS AMENDMENT SHALL BE CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS (INCLUDING 735 ILCS 105/5-1 ET
SEQ. BUT OTHERWISE WITHOUT REGARD TO THE CONFLICT OF LAWS PROVISIONS) OF THE STATE OF ILLINOIS, BUT GIVING EFFECT TO FEDERAL LAWS APPLICABLE TO NATIONAL BANKS. 
 7. Counterparts. This Amendment may be executed in any number of counterparts, each of which when so executed shall be deemed an original and all of which taken together shall constitute one and the same
agreement. 
 8. Headings. Section headings in this Amendment are included herein for convenience of reference only and shall not
constitute a part of this Amendment for any other purpose. 
 [Signature Pages Follow] 
  

 4 

 IN WITNESS WHEREOF, the Borrower, the Administrative Agent and the Lenders have executed this Amendment
as of the date first above written. 
  

			
	 BIO-RAD LABORATORIES, INC.,

	as the Borrower
		
	 By:
	 	 /s/ Ronald W. Hutton

	 Name:
	 	Ronald W. Hutton
	 Title:
	 	Treasurer
	
	 JPMORGAN CHASE BANK, N.A.,

	Individually as a Lender, as Principal Issuing Lender and as Administrative Agent
		
	 By:
	 	 /s/ Sanjna Daphtary

	 Name:
	 	Sanjna Daphtary
	 Title:
	 	Underwriter
	
	 WELLS FARGO BANK, N.A.,

	Individually as a Lender and as a Syndication Agent
		
	 By:
	 	 /s/ Michael Jones

	 Name:
	 	Michael Jones
	 Title:
	 	Assistant Vice President
	
	 UNION BANK OF CALIFORNIA, N.A.,

	Individually as a Lender and as a Syndication Agent
		
	 By:
	 	 /s/ Peter Sitov

	 Name:
	 	Peter Sitov
	 Title:
	 	Senior Vice President

  

 5 

			
	 ABN AMRO BANK N.V.,

	Individually as a Lender and as a Documentation Agent
		
	By:	 	 /s/ Michele Costello

	Name:	 	Michele Costello
	Title:	 	Director
		
	By:	 	 /s/ Marc Brandyke

	Name:	 	Marc Brandyke
	Title:	 	Associate
	
	 BNP PARIBAS,

	Individually as a Lender and as a Documentation Agent
		
	By:	 	 /s/ Katherine Wolfe

	Name:	 	Katherine Wolfe
	Title:	 	Managing Director
		
	By:	 	 /s/ Sandy Bertram

	Name:	 	Sandy Bertram
	Title:	 	Vice President
	
	 COMERICA BANK,

	Individually as a Lender
		
	By:	 	 /s/ Don R. Carruth

	Name:	 	Don R. Carruth
	Title:	 	Assistant Vice President
	
	 U.S. BANK NATIONAL ASSOCIATION,

	Individually as a Lender
		
	By:	 	 /s/ Conan Schleicher

	Name:	 	Conan Schleicher
	Title:	 	Vice President

  

 6 

			
	 THE NORTHERN TRUST COMPANY,

	 Individually as a Lender

		
	 By:
	 	 /s/ John E. Burda

	 Name:
	 	John E. Burda
	 Title:
	 	Vice President

  

 7Amendment No. 5 to the 1995 Plan

 EXHIBIT 4.3 
 INDEVUS PHARMACEUTICALS, INC. 
 AMENDMENT NO. 5 TO 1995 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED

 This Amendment No. 5 to the Indevus Pharmaceuticals, Inc. 1995 Employee Stock Purchase Plan, as amended (the “1995
Plan”) is effective as of April 17, 2007. 
 Pursuant to the authorization granted by the stockholders and the Board of Directors
of Indevus Pharmaceuticals, Inc., the 1995 Plan is hereby amended as follows: 
  

	 	1.	Section 4 of the 1995 Plan is hereby amended by deleting the words “Eight Hundred Thousand (800,000)” and replacing such words with “One Million Fifty Thousand
(1,050,000)”; 

  

	 	2.	The last paragraph of the plan is deleted in its entirety and placed with the following: 

 “The foregoing Indevus Pharmaceuticals, Inc. 1995 Employee Stock Purchase Plan was duly adopted by the Board of Directors of the Company on the 3rd day of February, 1995, and amended on
February 21,1996, March 8, 2000, June 6, 2001, March 11, 2003, March 9, 2005 and April 17, 2007.”; and 
  

	 	3.	Except as expressly amended hereby, the 1995 Plan shall remain in full force and effect. 

 IN WITNESS WHEREOF, the Company has duly executed this Amendment No. 5 to be effective as the date first above written. 
  

					
	INDEVUS PHARMACEUTICALS, INC.
		
	By:	 	/s/ Glenn L. Cooper
		 	Name:	 	Glenn L. Cooper
		 	Title:	 	Chief Executive Officer and Chairman of the Board

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}]]